Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 4 | 2024 | 1266 | 1.410 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2024 | 329 | 1.270 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 930 | 1.020 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2025 | 9442 | 0.860 |
Why?
|
Ependymoma | 2 | 2023 | 328 | 0.820 |
Why?
|
Spinal Cord Neoplasms | 1 | 2023 | 263 | 0.730 |
Why?
|
Paget Disease, Extramammary | 1 | 2021 | 51 | 0.730 |
Why?
|
Glioma | 8 | 2025 | 3532 | 0.730 |
Why?
|
Brain Neoplasms | 11 | 2025 | 9213 | 0.690 |
Why?
|
Photons | 2 | 2020 | 595 | 0.670 |
Why?
|
Skin Neoplasms | 4 | 2024 | 5864 | 0.670 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 493 | 0.650 |
Why?
|
Medulloblastoma | 2 | 2020 | 683 | 0.610 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2018 | 54 | 0.590 |
Why?
|
Radiotherapy | 2 | 2023 | 1506 | 0.590 |
Why?
|
Tumor Escape | 1 | 2020 | 372 | 0.570 |
Why?
|
Hematologic Diseases | 1 | 2020 | 498 | 0.540 |
Why?
|
Radiotherapy Dosage | 7 | 2024 | 2920 | 0.530 |
Why?
|
Vascular Malformations | 2 | 2021 | 469 | 0.520 |
Why?
|
Hyperpigmentation | 1 | 2017 | 116 | 0.510 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2021 | 812 | 0.510 |
Why?
|
Radiation Oncology | 1 | 2022 | 572 | 0.510 |
Why?
|
Cerebellar Neoplasms | 1 | 2020 | 591 | 0.510 |
Why?
|
Radiosurgery | 2 | 2021 | 1346 | 0.480 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1019 | 0.480 |
Why?
|
Capillaries | 1 | 2017 | 756 | 0.460 |
Why?
|
Sarcoma | 2 | 2023 | 1806 | 0.460 |
Why?
|
Child | 26 | 2025 | 80969 | 0.450 |
Why?
|
Leukemia | 1 | 2022 | 1520 | 0.450 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1060 | 0.440 |
Why?
|
Mitochondrial Proteins | 3 | 2015 | 980 | 0.420 |
Why?
|
Alopecia | 1 | 2017 | 416 | 0.420 |
Why?
|
Meningeal Neoplasms | 1 | 2021 | 1258 | 0.400 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1399 | 0.390 |
Why?
|
Retrospective Studies | 21 | 2025 | 81892 | 0.390 |
Why?
|
Graft vs Host Disease | 2 | 2022 | 3048 | 0.390 |
Why?
|
Germinoma | 2 | 2022 | 132 | 0.360 |
Why?
|
Neoplasms | 9 | 2023 | 22390 | 0.350 |
Why?
|
Abnormalities, Multiple | 1 | 2017 | 1423 | 0.350 |
Why?
|
Amyotrophic Lateral Sclerosis | 3 | 2015 | 1473 | 0.340 |
Why?
|
Cell Cycle Proteins | 2 | 2019 | 3450 | 0.340 |
Why?
|
Motor Neurons | 1 | 2015 | 872 | 0.340 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3951 | 0.330 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2960 | 0.300 |
Why?
|
Vincristine | 2 | 2020 | 1040 | 0.300 |
Why?
|
Adolescent | 16 | 2025 | 89247 | 0.290 |
Why?
|
Craniotomy | 3 | 2016 | 747 | 0.280 |
Why?
|
Antioxidants | 1 | 2015 | 1673 | 0.280 |
Why?
|
Nuclear Proteins | 3 | 2019 | 5803 | 0.280 |
Why?
|
Child, Preschool | 11 | 2025 | 42684 | 0.270 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2022 | 5716 | 0.270 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2565 | 0.260 |
Why?
|
Humans | 49 | 2025 | 768887 | 0.250 |
Why?
|
Young Adult | 13 | 2024 | 60110 | 0.240 |
Why?
|
Immunotherapy | 1 | 2020 | 4755 | 0.230 |
Why?
|
Temporal Muscle | 1 | 2023 | 36 | 0.220 |
Why?
|
Growth Charts | 1 | 2023 | 60 | 0.210 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5434 | 0.210 |
Why?
|
Busulfan | 1 | 2022 | 259 | 0.190 |
Why?
|
Whole-Body Irradiation | 1 | 2022 | 435 | 0.190 |
Why?
|
Sturge-Weber Syndrome | 1 | 2022 | 89 | 0.190 |
Why?
|
Choroid Neoplasms | 1 | 2022 | 177 | 0.190 |
Why?
|
Pineal Gland | 1 | 2022 | 158 | 0.190 |
Why?
|
Female | 28 | 2025 | 397464 | 0.180 |
Why?
|
Hemangioendothelioma | 1 | 2021 | 112 | 0.180 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13593 | 0.180 |
Why?
|
Mutation | 4 | 2022 | 30266 | 0.180 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.180 |
Why?
|
Prognosis | 5 | 2025 | 30044 | 0.170 |
Why?
|
Ribonuclease III | 1 | 2022 | 271 | 0.170 |
Why?
|
Sex Reassignment Surgery | 1 | 2023 | 165 | 0.170 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 42 | 0.170 |
Why?
|
Blood Cell Count | 1 | 2020 | 406 | 0.170 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2020 | 108 | 0.170 |
Why?
|
Male | 25 | 2025 | 365249 | 0.160 |
Why?
|
Lymphatic Abnormalities | 1 | 2021 | 134 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11886 | 0.160 |
Why?
|
Teratoma | 1 | 2022 | 405 | 0.160 |
Why?
|
Relative Biological Effectiveness | 1 | 2020 | 313 | 0.160 |
Why?
|
Pyrans | 1 | 2019 | 49 | 0.160 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 385 | 0.160 |
Why?
|
Morpholines | 2 | 2019 | 584 | 0.160 |
Why?
|
Cranial Irradiation | 1 | 2021 | 395 | 0.160 |
Why?
|
Infratentorial Neoplasms | 1 | 2019 | 99 | 0.160 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 877 | 0.150 |
Why?
|
Tattooing | 1 | 2018 | 57 | 0.150 |
Why?
|
Testicular Neoplasms | 2 | 2022 | 805 | 0.150 |
Why?
|
Sarcoma, Kaposi | 1 | 2021 | 375 | 0.150 |
Why?
|
Hemangioma | 1 | 2022 | 727 | 0.140 |
Why?
|
Dermatitis, Contact | 1 | 2017 | 134 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 622 | 0.140 |
Why?
|
Melanoma, Experimental | 1 | 2020 | 559 | 0.130 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 8559 | 0.130 |
Why?
|
Transplantation, Homologous | 2 | 2022 | 4835 | 0.130 |
Why?
|
Patient Positioning | 1 | 2018 | 332 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2025 | 39394 | 0.130 |
Why?
|
Oxidative Stress | 3 | 2015 | 3138 | 0.130 |
Why?
|
Radiotherapy, Conformal | 1 | 2018 | 549 | 0.120 |
Why?
|
Infant | 5 | 2025 | 36541 | 0.120 |
Why?
|
Gender Identity | 1 | 2021 | 770 | 0.120 |
Why?
|
Arm | 1 | 2017 | 590 | 0.120 |
Why?
|
RNA-Binding Protein FUS | 1 | 2015 | 77 | 0.120 |
Why?
|
Central Nervous System | 1 | 2021 | 1345 | 0.110 |
Why?
|
Brain Stem | 1 | 2019 | 862 | 0.110 |
Why?
|
Adaptive Immunity | 1 | 2019 | 733 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 919 | 0.110 |
Why?
|
Histone Deacetylases | 1 | 2018 | 718 | 0.110 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 1679 | 0.110 |
Why?
|
Immune Tolerance | 2 | 2020 | 2323 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 542 | 0.110 |
Why?
|
NF-kappa B | 2 | 2020 | 2492 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 778 | 0.110 |
Why?
|
Serum Albumin | 1 | 2016 | 677 | 0.100 |
Why?
|
Carrier Proteins | 2 | 2016 | 4940 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2022 | 65485 | 0.100 |
Why?
|
Leg | 1 | 2017 | 1089 | 0.100 |
Why?
|
Pyrimidines | 2 | 2022 | 3050 | 0.100 |
Why?
|
Quality Improvement | 3 | 2016 | 3856 | 0.100 |
Why?
|
Rare Diseases | 1 | 2017 | 630 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1203 | 0.100 |
Why?
|
Mucous Membrane | 1 | 2015 | 659 | 0.100 |
Why?
|
Adult | 9 | 2023 | 223818 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1601 | 0.100 |
Why?
|
Radiation Dosage | 1 | 2020 | 1970 | 0.100 |
Why?
|
Postoperative Complications | 4 | 2018 | 15889 | 0.090 |
Why?
|
Barrett Esophagus | 1 | 2015 | 495 | 0.090 |
Why?
|
Macrophages | 3 | 2023 | 5800 | 0.090 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6856 | 0.090 |
Why?
|
Recurrence | 1 | 2023 | 8512 | 0.090 |
Why?
|
Risk Assessment | 4 | 2025 | 24330 | 0.090 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6401 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6546 | 0.090 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1483 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 4 | 2025 | 36861 | 0.080 |
Why?
|
Neuroprotective Agents | 1 | 2015 | 958 | 0.080 |
Why?
|
Prospective Studies | 4 | 2021 | 54950 | 0.080 |
Why?
|
Time Factors | 3 | 2020 | 40266 | 0.080 |
Why?
|
DNA Damage | 1 | 2018 | 2472 | 0.070 |
Why?
|
Sepsis | 1 | 2022 | 2609 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1181 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2543 | 0.070 |
Why?
|
Massachusetts | 1 | 2021 | 8888 | 0.070 |
Why?
|
Evolution, Molecular | 1 | 2015 | 1894 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1642 | 0.070 |
Why?
|
Animals | 11 | 2023 | 169408 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2350 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10115 | 0.060 |
Why?
|
Cell Survival | 1 | 2015 | 5794 | 0.060 |
Why?
|
Databases, Factual | 2 | 2017 | 8095 | 0.060 |
Why?
|
Esophageal Neoplasms | 1 | 2015 | 1674 | 0.060 |
Why?
|
Disease Models, Animal | 4 | 2019 | 18366 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2059 | 0.060 |
Why?
|
Aged | 6 | 2024 | 171790 | 0.060 |
Why?
|
Mice, Inbred C57BL | 3 | 2020 | 22381 | 0.060 |
Why?
|
Mice | 9 | 2023 | 82074 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4064 | 0.050 |
Why?
|
Incidence | 2 | 2019 | 21545 | 0.050 |
Why?
|
Mice, Transgenic | 1 | 2015 | 9564 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16735 | 0.050 |
Why?
|
Uridine | 1 | 2022 | 135 | 0.050 |
Why?
|
Mice, Nude | 2 | 2019 | 3631 | 0.050 |
Why?
|
Signal Transduction | 3 | 2020 | 23652 | 0.050 |
Why?
|
Transcription Factors | 2 | 2019 | 12174 | 0.050 |
Why?
|
Length of Stay | 1 | 2015 | 6525 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1913 | 0.050 |
Why?
|
Disease Progression | 2 | 2015 | 13677 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2021 | 26394 | 0.040 |
Why?
|
Anal Canal | 1 | 2023 | 375 | 0.040 |
Why?
|
Proteins | 1 | 2015 | 6011 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 13510 | 0.040 |
Why?
|
Cerebral Cortex | 1 | 2016 | 5834 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15955 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 223740 | 0.040 |
Why?
|
Aged, 80 and over | 1 | 2024 | 59738 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 13054 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 9618 | 0.040 |
Why?
|
Vagina | 1 | 2023 | 848 | 0.040 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.030 |
Why?
|
Protons | 1 | 2022 | 1113 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 17174 | 0.030 |
Why?
|
Neurons | 1 | 2016 | 9524 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 26384 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2020 | 726 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2018 | 349 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 859 | 0.030 |
Why?
|
Cell Polarity | 1 | 2019 | 639 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1621 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 2460 | 0.030 |
Why?
|
INDEL Mutation | 1 | 2015 | 267 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2063 | 0.030 |
Why?
|
Standard of Care | 1 | 2019 | 570 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2023 | 2884 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2020 | 11119 | 0.030 |
Why?
|
Preoperative Period | 1 | 2016 | 565 | 0.030 |
Why?
|
Integrases | 1 | 2016 | 520 | 0.030 |
Why?
|
Triazoles | 1 | 2019 | 904 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2015 | 930 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 787 | 0.030 |
Why?
|
Interleukin-13 | 1 | 2015 | 391 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2015 | 450 | 0.030 |
Why?
|
GTPase-Activating Proteins | 1 | 2015 | 469 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14795 | 0.030 |
Why?
|
Methylation | 1 | 2015 | 1078 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6131 | 0.020 |
Why?
|
Movement | 1 | 2018 | 1490 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3621 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2024 | 3411 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2015 | 1157 | 0.020 |
Why?
|
Arginine | 1 | 2015 | 932 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13317 | 0.020 |
Why?
|
Mitosis | 1 | 2016 | 1181 | 0.020 |
Why?
|
Survival Rate | 1 | 2025 | 12873 | 0.020 |
Why?
|
Cytoplasm | 1 | 2015 | 1505 | 0.020 |
Why?
|
RNA Splicing | 1 | 2015 | 905 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18454 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2931 | 0.020 |
Why?
|
Intracranial Hemorrhages | 1 | 2016 | 811 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2015 | 1714 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6232 | 0.020 |
Why?
|
Age of Onset | 1 | 2017 | 3346 | 0.020 |
Why?
|
Thalamus | 1 | 2016 | 1050 | 0.020 |
Why?
|
Neurogenesis | 1 | 2016 | 865 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2015 | 3775 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2054 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2015 | 1320 | 0.020 |
Why?
|
Axons | 1 | 2016 | 1678 | 0.020 |
Why?
|
Spinal Cord | 1 | 2016 | 1813 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7245 | 0.020 |
Why?
|
Program Evaluation | 1 | 2016 | 2507 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5707 | 0.020 |
Why?
|
Autophagy | 1 | 2015 | 1351 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8055 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2016 | 2431 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15875 | 0.020 |
Why?
|
Reoperation | 1 | 2016 | 4342 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4265 | 0.020 |
Why?
|
Computer Simulation | 1 | 2018 | 6289 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3925 | 0.010 |
Why?
|
Overweight | 1 | 2016 | 2445 | 0.010 |
Why?
|
Skin | 1 | 2018 | 4507 | 0.010 |
Why?
|
Cytokines | 1 | 2020 | 7453 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4926 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10486 | 0.010 |
Why?
|
Cell Movement | 1 | 2016 | 5216 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2016 | 3206 | 0.010 |
Why?
|
Apoptosis | 1 | 2020 | 9528 | 0.010 |
Why?
|
Chronic Disease | 1 | 2018 | 9384 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3489 | 0.010 |
Why?
|
Protein Binding | 1 | 2015 | 9344 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7602 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15603 | 0.010 |
Why?
|
Patient Readmission | 1 | 2015 | 3313 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10591 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12563 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7609 | 0.010 |
Why?
|
Risk Factors | 2 | 2018 | 74971 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11262 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8384 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15471 | 0.010 |
Why?
|
United States | 2 | 2018 | 73180 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20244 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20776 | 0.010 |
Why?
|